Tag Archives: pTau181

Trontinemab Brainshuttle Study Achieves 91 Percent Amyloid Clearance and Sets Stage for 2025 Phase III Rollout

(IN BRIEF) Roche’s ongoing Phase Ib/IIa Brainshuttle™ AD study of trontinemab shows that 91 percent of participants reach amyloid PET negativity, with ARIA‑E rates under 5 percent. The company has outlined Phase III TRONTIER 1 and 2 trials in early symptomatic Alzheimer’s for 2025, plus a planned … Read the full press release

Roche Propels Alzheimer’s Treatment Forward with Rapid Amyloid Clearance and Breakthrough Diagnostic Test

(IN BRIEF) Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, achieves rapid and dose-dependent reductions of amyloid plaques in the brain, with significant biomarker improvements observed in fluid … Read the full press release